Abstract
Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having numerous effects and functions. The use of on demand PDE5 inhibitors (-Is) for the treatment of erectile dysfunction (ED) has recently obtained approval for chronic daily dosing for the same indication. There are published data supporting the use of PDE5-Is for the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Additional reports suggest benefit by these agents in patients with chronic heart failure, pulmonary hypertension, essential hypertension, and for the treatment of ischemia. Various central nervous system disorders have been described as targets by PDE5-Is. Sildenafil may have a potential therapeutic indication as a cognitive enhancer in age-related cerebral conditions. There is preclinical evidence for further investigation of the use of PDE5A -Is to improve recovery of cerebral function in humans after stroke by enhancing angiogenesis, neurogenesis and improving neurologic function. Sildenafil delays intestinal ulceration by an increase in the secretion of mucus/fluid and a decrease in hypermotility, and has a protective effect in reducing gastric damage. Larger scale, well designed clinical trials are needed to ascertain the safety, efficacy and cost-effectiveness of PDE5-Is in the future treatment of both urologic and non-urologic diseases. In this review, potential applications of PDE5-Is on urologic, cardiovascular, gastrointestinal, and central nervous system disorders will be updated.
Keywords: Phoshodiesterase enzyme, sildenafil, stroke, cardiovascular disease, pulmonary hypertension, priapism, erectile dysfunction (ED), hypermotility, ischemia, central nervous system disorders.
Current Pharmaceutical Design
Title:PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Volume: 18 Issue: 34
Author(s): Serap Gur, Philip J. Kadowitz, Ege Can Serefoglu and Wayne J.G. Hellstrom
Affiliation:
Keywords: Phoshodiesterase enzyme, sildenafil, stroke, cardiovascular disease, pulmonary hypertension, priapism, erectile dysfunction (ED), hypermotility, ischemia, central nervous system disorders.
Abstract: Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having numerous effects and functions. The use of on demand PDE5 inhibitors (-Is) for the treatment of erectile dysfunction (ED) has recently obtained approval for chronic daily dosing for the same indication. There are published data supporting the use of PDE5-Is for the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Additional reports suggest benefit by these agents in patients with chronic heart failure, pulmonary hypertension, essential hypertension, and for the treatment of ischemia. Various central nervous system disorders have been described as targets by PDE5-Is. Sildenafil may have a potential therapeutic indication as a cognitive enhancer in age-related cerebral conditions. There is preclinical evidence for further investigation of the use of PDE5A -Is to improve recovery of cerebral function in humans after stroke by enhancing angiogenesis, neurogenesis and improving neurologic function. Sildenafil delays intestinal ulceration by an increase in the secretion of mucus/fluid and a decrease in hypermotility, and has a protective effect in reducing gastric damage. Larger scale, well designed clinical trials are needed to ascertain the safety, efficacy and cost-effectiveness of PDE5-Is in the future treatment of both urologic and non-urologic diseases. In this review, potential applications of PDE5-Is on urologic, cardiovascular, gastrointestinal, and central nervous system disorders will be updated.
Export Options
About this article
Cite this article as:
Gur Serap, J. Kadowitz Philip, Can Serefoglu Ege and J.G. Hellstrom Wayne, PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update, Current Pharmaceutical Design 2012; 18 (34) . https://dx.doi.org/10.2174/138161212803307554
DOI https://dx.doi.org/10.2174/138161212803307554 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Editorial [Hot Topic: Gender Differences in Cardiovascular Diseases. A Need for Action (Executive Guest Editors: Giuseppe Barbaro and Giuseppe M.C. Rosano)]
Current Pharmaceutical Design Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Cannabinoid Receptors in Renal Diseases
Current Medicinal Chemistry Editorial (Thematic Issue: Vascular Damage In Systemic Sclerosis)
Current Rheumatology Reviews Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research Flavonoids and Linderone from Lindera oxyphylla and their Bioactivities
Combinatorial Chemistry & High Throughput Screening Mediterranean Diet and Longevity
Current Nutrition & Food Science Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening Lipid Management and Peripheral Arterial Disease
Current Drug Targets COPD Evaluation: Beyond the Airway Obstruction, a Follow Up
Current Respiratory Medicine Reviews Association of Thrombospondin-1 (N700S) and Thrombospond in-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians
Current Pharmaceutical Biotechnology Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Expression Activity of Selected Proangiogenic Factors in Patients with Limb Ischemia
Current Metabolomics Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews